Beta Cell Biology Consortium (BCBC)
Research Areas
At a Glance
- Status: Completed Consortium
- Year Launched: 2001
- Initiating Organization: Vanderbilt University
- Initiator Type: Academia
- Disease focus:
Type 1 Diabetes - Location: North America
Abstract
The Beta Cell Biology Consortium (BCBC) aims to facilitate research in the following areas and will be responsible for collaboratively generating the necessary reagents, mouse strains, antibodies, assays, protocols, technologies, and validation assays that are beyond the scope of any single research effort.
Mission
BCBC’s mission is to facilitate interdisciplinary collaborations to advance understanding of pancreatic islet development and function, with the goal of developing innovative therapies to correct the loss of beta cell mass in diabetes, including cell reprogramming, regeneration, and replacement.
Consortium History
BCBC was established by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH).
Structure & Governance
Activities within BCBC are overseen by both NIDDK staff members and participating scientists. A Steering Committee (SC), which consists of all BCBC principal investigators (PIs), meets on a semi-annual basis. An Executive Committee (EC) meets monthly by teleconference. An External Evaluation Committee serves to provide objective scientific input and guidance.
Financing
Currently, BCBC consists of more than 50 research laboratories, which are funded by U-01 cooperative agreements. Grant information can be found here: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-01-014.html, http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-04-017.html, http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-04-018.html, and http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-09-011.html
Impact/Accomplishment
Many of the BCBC investigator-initiated projects involve reagent-generating activities that will benefit the larger scientific community. The combination of programs and activities that together comprise BCBC should accelerate the pace of major new discoveries and progress within the field of beta cell biology.
Links/Social Media Feed
Homepage |
Points of Contact
The Beta Cell Biology Consortium
Vanderbilt Center for Stem Cell Biology
2213 Garland Avenue
9465 MRB IV
Nashville, TN 37232-0494
phone: 615.936.8327
fax: 615.322.6645
Sponsors & Partners
Brigham and Women’s Hospital |
Children’s Hospital of Philadelphia |
Cincinnati Children’s Hospital Medical Center |
CNRS – UMR 7225 |
Columbia University |
Copenhagen University |
DanStem, University of Copenhagen |
Duke University Medical Center |
Hadassah-Hebrew University Medical Center |
Hagedorn Research Institute |
Harvard /HHMI |
Hebrew University-Hadassah Medical School |
Icahn School of Medicine at Mount Sinai |
Imperial College London |
Indiana University |
Karolinska University |
Massachusetts General Hospital |
Massachusetts Institute of Technology |
Max Planck Institute for Heart and Lung Research |
McEwen Centre for Regenerative Medicine/ University Health Network |
Mount Sinai School of Medicine |
Northwestern University |
Oregon Health & Sciences University |
Phillips-Universität |
Seattle Children’s Research Institute |
Stanford University |
The Jackson Laboratory |
The University of Chicago |
University of California, Los Angeles |
University of California, San Diego |
University of California, San Francisco |
University of Colorado |
University of Geneva Faculty of Medicine |
University of Massachusetts |
University of Massachusetts Medical School |
University of Massachusetts Medical School |
University of Pennsylvania |
University of Pittsburgh |
University of Texas Southwestern Medical Center |
University of Toronto |
Vanderbilt University |
Vanderbilt University Medical Center |
Vrije Univesiteit, Brussels |